AIDS & Health News

DUBLIN--(BUSINESS WIRE)--The "HIV Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for HIV Drugs was valued at US$32.8 Billion in 2024 and is projected to reach US$44.5 Billion by 2030, growing at a CAGR of 5.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth in the HIV drugs market is driven by sever...

LOS ANGELES--(BUSINESS WIRE)--This World Tuberculosis (TB) Day, observed on March 24, AIDS Healthcare Foundation (AHF) teams worldwide join government and civil society partners in calling for more substantial political commitments, increased funding, and expanded access to TB services. AHF teams’ World TB Day events will call for action and help raise awareness about TB – the world’s deadliest infectious disease, the leading cause of death for people living with HIV, and a major cause of death...

DUBLIN--(BUSINESS WIRE)--The "HIV Rapid Test Kits Market - Focused Insights 2025-2030" report has been added to ResearchAndMarkets.com's offering. The HIV Rapid Test Kits Market was valued at USD 1.49 billion in 2024, and is projected to reach USD 1.82 billion by 2030, rising at a CAGR of 3.39%. North America dominates and holds the largest global HIV rapid test kits market share of over 30%. The North American market is one of the largest and most mature markets for HIV rapid test kits. The re...

FRISCO, Texas & FORT WAYNE, Ind.--(BUSINESS WIRE)--SOLEO HEALTH INTRODUCES NEW AMBULATORY INFUSION SUITE IN FORT WAYNE...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV acquisition for Apretude, the only long-acting injectable approved for HIV prevention. Real-world data were also presented for Cabenuva, the only approved, complete long-acting injectable treatment regimen, showing its effectiveness in the three years since it has been avail...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.1 The study found that N6LS (VH3810109 or VH109), given every four months in combination with monthly cabotegravir long-acting (CAB LA), successfully kept viral levels suppressed in adults living with HIV who were already stable on treatment. It was also well tolerated by particip...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Data from Phase 3 Trials that Show Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir Maintained HIV-1 Viral Suppression...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). The new findings reflect a transformative portfolio and a rapidly advancing forward-looking pipeline focused on expanding choices and enhancing outcomes for those with HIV, while continuing to reach towar...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from two phase IIa proof-of-concept studies of investigational antiretroviral therapies VH4524184 (VH184) and VH4011499 (VH499). These findings, presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, U.S., support the continued development of these two compounds as distinct o...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). The data were presented during an oral abstract session at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) and were also published today in T...